How have DDDD shares performed in 2024?

4D pharma's stock was trading at GBX 16.66 at the beginning of the year. Since then, DDDD stock has increased by 0.0% and is now trading at GBX 16.66. View the best growth stocks for 2024 here .

How were 4D pharma's earnings last quarter?

4D pharma plc (LON:DDDD) posted its earnings results on Wednesday, September, 30th. The company reported ($14.06) earnings per share (EPS) for the quarter.

What other stocks do shareholders of 4D pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 4D pharma investors own include Amigo (AMGO) , Adamis Pharmaceuticals (ADMP) , American Airlines Group (AAL) , Boeing (BA) , Cineworld Group (CINE) , Cray (CRAY) , Omega Diagnostics Group (ODX) , Oracle (ORCL) , Tullow Oil (TLW) .

How do I buy shares of 4D pharma?

Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:DDDD

4D pharma (DDDD) Share Price, News & Analysis

→ The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad)

Free DDDD Stock Alerts

GBX 16.66

0.00 (0.00%)

(As of 11/8/2022)

Compare

Today's Range: 16.66
▼
16.66
50-Day Range: 16.66
▼
16.66
52-Week Range: 16.66
▼
16.66

Volume: 1.21 million shs
Average Volume: 2.96 million shs
Market Capitalization: £30.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get 4D pharma alerts:

Ad Weiss Ratings

The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

About 4D pharma Stock (LON:DDDD)

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

DDDD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DDDD Stock News Headlines

March 1, 2024 | markets.businessinsider.com

4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

February 7, 2024 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

February 7, 2024 | msn.com

4D Molecular Therapeutics up 3%, prices $300M equity

February 5, 2024 | marketwatch.com

4D Molecular Shares Hit 52-Week High After 4D-150 Eye Treatment Trial

February 5, 2024 | realmoney.thestreet.com

How to Trade a Surging 4D Molecular Therapeutics

February 5, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)

February 5, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Valeo Pharma (OtherVPHIF) and AbbVie (ABBV)

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

January 30, 2024 | news.yahoo.com

Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businesses

November 27, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Merus (MRUS), 4D Molecular Therapeutics (FDMT) and Inari Medical (NARI)

November 11, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Xenon (XENE), Adverum Biotechnologies (ADVM) and 4D Molecular Therapeutics (FDMT)

November 2, 2023 | markets.businessinsider.com

Positive Clinical Trial Results and Future Prospects Reinforce Buy Rating for 4D Molecular Therapeutics: An Analysis by Geulah Livshits

July 11, 2023 | markets.businessinsider.com

BMO Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)

July 5, 2023 | msn.com

4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst

April 28, 2023 | marketwatch.com

4D Molecular Down 25% After Wet AMD Drug Update

April 27, 2023 | markets.businessinsider.com

What's Going On With 4D Molecular Therapeutics Stock Today

March 24, 2023 | marketwatch.com

Microbiome Therapeutics Market Current Trends, Segmentation, Key Players and Analysis Till 2035

February 14, 2023 | marketwatch.com

Pharmacy Management System Market Scenario 2023 to 2028: New Developments, Economic Situation and Growth Projection

January 20, 2023 | finance.yahoo.com

Human Microbiome Market Report (2022 to 2030) – Obiome, 4D Pharma, Vedanta Biosciences, Second Genome, Ferring Pharmaceuticals

December 30, 2022 | thetimes.co.uk

4D Pharma rescue by Armistice to face vote

October 5, 2022 | finance.yahoo.com

4D pharma plc (DDDD.L)

September 26, 2022 | nasdaq.com

The past year for 4D Molecular Therapeutics (NASDAQ:FDMT) investors has not been profitable

June 30, 2022 | apnews.com

4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq

June 25, 2022 | thetimes.co.uk

Woodford stock pick 4D Pharma collapses

June 24, 2022 | finance.yahoo.com

Update on Suspension of Trading

May 27, 2022 | proactiveinvestors.com.au

4D Pharma outlines phase II plans for promising cancer drug candidate

See More Headlines

Receive DDDD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/30/2020
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: LON:DDDD
CUSIP: N/A
CIK: N/A
Web: www.4dpharmaplc.com
Phone: +44-113-8950130
Fax: N/A
Employees: 106
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (15.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-31,940,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -89.48%
Return on Assets: -42.64%

Debt

Debt-to-Equity Ratio: 39.50
Current Ratio: 5.21
Quick Ratio: 4.72

Sales & Book Value

Annual Sales: £718,000.00
Price / Sales: 41.84
Cash Flow: GBX 11.60 per share
Price / Cash Flow: 1.44
Book Value: GBX 18 per share
Price / Book: 0.93

Miscellaneous

Outstanding Shares: 180,340,000
Free Float: N/A
Market Cap: £30.04 million
Optionable: Not Optionable
Beta: 2.63

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Duncan Joseph Peyton (Age 53)
CEO & Exec. Director
Comp: $254k
Dr. Alexander James Stevenson Ph.D. (Age 51)
Chief Scientific Officer & Exec. Director
Comp: $218k
Mr. John Brendan Doyle (Age 45)
Chief Financial Officer
Ms. Fay Weston
Head of Investor Relations
Mr. Adrian Murray
Gen. Counsel (Interim)
Mr. Glenn Dourado
Exec. VP of Corp. Devel.
Ms. Lucy Christie
VP of HR
Mr. Christophe Carite
Sr. VP of CMC & Process Devel.
Ms. Imke Mulder
Exec. VP of Research

Key Competitors

View All Competitors

DDDD Stock Analysis - Frequently Asked Questions

How have DDDD shares performed in 2024?: 4D pharma's stock was trading at GBX 16.66 at the beginning of the year. Since then, DDDD stock has increased by 0.0% and is now trading at GBX 16.66.
View the best growth stocks for 2024 here.
How were 4D pharma's earnings last quarter?: 4D pharma plc (LON:DDDD) posted its earnings results on Wednesday, September, 30th. The company reported ($14.06) earnings per share (EPS) for the quarter.
What other stocks do shareholders of 4D pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other 4D pharma investors own include Amigo (AMGO), Adamis Pharmaceuticals (ADMP), American Airlines Group (AAL), Boeing (BA), Cineworld Group (CINE), Cray (CRAY), Omega Diagnostics Group (ODX), Oracle (ORCL), Tullow Oil (TLW).
How do I buy shares of 4D pharma?: Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DDDD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial